Lentiviral Vectors for Ocular Gene Therapy
Open accessThe DOI matches its Crossref record; 206 of the 208 references it cites were found in a registry or an index.
Abstract
This review offers the basics of lentiviral vector technologies, their advantages and pitfalls, and an overview of their use in the field of ophthalmology. First, the description of the global challenges encountered to develop safe and efficient lentiviral recombinant vectors for clinical application is provided. The risks and the measures taken to minimize secondary effects as well as new strategies using these vectors are also discussed. This review then focuses on lentiviral vectors specifically designed for ocular therapy and goes over preclinical and clinical studies describing their safety and efficacy. A therapeutic approach using lentiviral vector-mediated gene therapy is currently being developed for many ocular diseases, e.g., aged-related macular degeneration, retinopathy of prematurity, inherited retinal dystrophies (Leber congenital amaurosis type 2, Stargardt disease, Usher syndrome), glaucoma, and corneal fibrosis or engraftment rejection. In summary, this review shows how lentiviral vectors offer an interesting alternative for gene therapy in all ocular compartments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Entry and integration of HIV-1. Structural and enzymatic HIV-1 genes are presented in gray boxes, HIV-1 regulatory factors in green, HIV-1 accessory factors in blue, and LTR in yellow. Corresponding proteins are represented with the same color code in a schematic HIV-1 particle. The different processes, from binding to the cell membrane to the integration of the provirus DNA into the host genome, are depicted with viral protein required at each step. The timing of uncoating of the capsid (CA) and the role of CA is still unclear, as discussed in a recent review [11]. The Gag gene codes for matrix proteins (MA), capsid proteins (CA), and nucleocapsid protein (NC). The Pol gene encodes for the reverse transcriptase (RT), the integrase (IN), and the protease (PRO).](https://figures.cochat.ai/paper-figures/f17286d4d038409bb4bfc035d2358af9/lentiviral-vectors-for-ocular-gene-therapy-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, they carry risks for insertional mutagenesis and germline transmission and may elicit more inflammatory responses than AAVs.54,56,73”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 1×
“Then the SA, SD, cPPT, and RRE sequences are essential for the preparation and packaging of the transfer cassette into the recombinant viral particle and its import into the host cell nuclei [3,7].”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 1×
“New editing strategies, based on modified Cas9, allow for specifically replacing a cytosine or an adenine without inducing DNA double-strand break [156].”
BackgroundLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587 · cited 1×
“Indeed, since one of its first use in human clinics, gene therapy using retroviruses (Moloney retrovirus), despite showing at first an impressive efficiency, is unfortunately followed by a lethal risk of mutational insertion [23,24].”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Indeed, since one of its first use in human clinics, gene therapy using retroviruses (Moloney retrovirus), despite showing at first an impressive efficiency, is unfortunately followed by a lethal risk of mutational insertion [23,24].”
BackgroundInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“This indicates that, unlike other retroviruses (gammaretroviral vectors [29]), LV insertional mutation event is a risk low enough to support the safety of LV for clinical use.”
BackgroundSelf-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis
Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H.-J., Benedict, W., & Bouck, N. P. (1999) · Science · doi:10.1126/science.285.5425.245 · Cited by 1,505 · cited 1×
“PEDF has both anti-angiogenic and neuroprotective actions [135,136].”
BackgroundNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · cited 1×
“Moreover, recombination at the post-transcriptional level, for example, between splicing sites of the viral RNA and the host RNAs, is another treatment to consider [19], even if it can sometimes be beneficial for the treatment [20].”
BackgroundDefective myosin VIIA gene responsible for Usher syndrome type IB
Well, D., Blanchard, S., Kaplan, J., Guilford, P., Gibson, F., Walsh, J., Mburu, P., Varela, A., Levilliers, J., Weston, M. D., et al. (1995) · Nature · doi:10.1038/374060a0 · Cited by 1,068 · cited 1×
“The shaker1 mouse model partially recapitulates the disease with congenital deafness appearance and vestibular dysfunction due to mutations in the Myo7a gene [159].”
Background
Cited by
Viral Vector-Based Gene Therapy
Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., & Yang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097736 · Cited by 200
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
The concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40
“By affecting the outflow in Schlemm’s canal, it leads to the regulation of aqueous humor outflow (Arsenijevic et al., 2022).”
BackgroundGenome Editing, A Superior Therapy for Inherited Retinal Diseases
Yan, A. L., Du, S. W., & Palczewski, K. (2022) · Vision Research · doi:10.1016/j.visres.2023.108192 · Cited by 40
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Ou, L., Setegne, M. T., Elliot, J., Shen, F., & Dassama, L. M. K. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00595 · Cited by 33
Metadata
- Authors
- Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C.
- Affiliations
- Unit Retinal Degeneration and Regeneration, Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, 1004 Lausanne, Switzerland
- Fondation Asile des Aveugles (CH)
- Hôpital Ophtalmique Jules-Gonin (CH)
- Corresponding author
- Kostic, Corinne
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-07-31
- Volume
- 14
- Issue
- 8
- Pages
- 1605
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9414879
- OpenAlex
- W4289203946
- Cited by
- 47
- References
- 208
- Citations by year
- 2026: 6 · 2025: 19 · 2024: 12 · 2023: 8 · 2022: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- IRIS (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fondation Asile des Aveugles (.)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- lentiviral vectors, ocular gene therapy, age-related macular degeneration, retinopathy of prematurity, inherited retinal disease, Stargardt disease, Usher syndrome, glaucoma, corneal fibrosis, preclinical and clinical studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lentiviral Vectors for Ocular Gene Therapy. https://app.cochat.ai/papers/10.3390/pharmaceutics14081605
- The paper
- Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022). Lentiviral Vectors for Ocular Gene Therapy. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14081605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.